Related Experiment Videos
Antiproliferative properties of toremifene on AIDS-related Kaposi's sarcoma cells
1Department of Radiation Oncology, Sydney Cancer Center, Royal Prince Alfred Hospital, Sydney, Australia. ahong@email.cs.nsw.gov.au
Background:
Kaposi's sarcoma (KS) is the most common neoplastic apoptosis manifestation of acquired immunodeficiency syndrome. Toremifene is known to upregulate transforming growth factor beta-1 (TGF-beta1), which is a growth-inhibitory factor for KS. We investigated the in vitro effect of toremifene on KS cells.
Methods:
MTT assay was used to measure the growth of four KS cell lines and a human umbilical vein endothelial (HUVE) cell line after incubation with toremifene. Reverse transcription polymerase chain reaction and ELISA were used to measure the level of TGF-beta1.
Results:
The IC(50) for the KS cells ranged from 2.2 to 3.2 microM, and 80% of the growth inhibition occurred within 24 h. Toremifene enhanced TGF-beta1 mRNA expression, and the level of TGF-beta1 increased from 103 to 473 pg/ml after 48 h of incubation. Toremifene had no effect on the growth of HUVE cells.
Conclusion:
Toremifene has a specific antiproliferative effect on KS cells. The stimulation of TGF-beta1 production may play a role in the antiproliferative process.
Insights
Toremifene effectively inhibits Kaposi
Area of Science:
- Oncology
- Virology
- Cell Biology
Background:
- Kaposi's sarcoma (KS) is a common cancer in individuals with acquired immunodeficiency syndrome (AIDS).
- Toremifene is known to increase transforming growth factor beta-1 (TGF-beta1), a KS growth inhibitor.
- This study explores toremifene's impact on KS cells.
Purpose of the Study:
- To evaluate the in vitro antiproliferative effects of toremifene on Kaposi's sarcoma cells.
- To determine the role of transforming growth factor beta-1 (TGF-beta1) in toremifene's action against KS.
Main Methods:
- Utilized MTT assays to assess the growth inhibition of four KS cell lines and human umbilical vein endothelial (HUVE) cells.
- Employed reverse transcription polymerase chain reaction (RT-PCR) and ELISA to quantify TGF-beta1 mRNA and protein levels.
Main Results:
- Toremifene demonstrated significant antiproliferative effects on KS cells, with IC(50) values between 2.2–3.2 microM.
- Observed an 80% growth inhibition of KS cells within 24 hours.
- Toremifene treatment increased TGF-beta1 mRNA expression and protein levels from 103 to 473 pg/ml over 48 hours.
- No significant impact on HUVE cell growth was noted.
Conclusions:
- Toremifene exhibits a specific antiproliferative effect on Kaposi's sarcoma cells.
- Increased TGF-beta1 production is implicated as a key mechanism in toremifene's anti-KS activity.